Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 12Paclitaxel 10Taxes 9Doxorubicin 7Cyclophosphamide 7Docetaxel 6Bevacizumab 6Lapatinib 5Filgrastim 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5Vorinostat 4tipifarnib 3pegfilgrastim 3cediranib 3Peripheral Blood Stem Cell Transplantation 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Carboplatin 3Capecitabine 3veliparib 2ixabepilone 2entinostat 2alvocidib 2Tamoxifen 2Radiotherapy 2Neoadjuvant Therapy 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms, Male × TIC10 compound × Clear all
NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡